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Comorbidities are increasingly recognized as crucial components of the heart failure
syndrome. Main speciﬁc challenges are polypharmacy, poor adherence to treat-
ments, psychological aspects, and the need of monitoring after discharge. The
chronic multimorbid patient therefore represents a speciﬁc heart failure phenotype
that needs an appropriate and continuous management over time. This supplement
issue covers the key points of a series of meeting coordinated by the Heart Failure
Association of the European Society of Cardiology (ESC), that have discussed the
issues surrounding the effective monitoring of our ever more complex and multimor-
bid heart failure patients. Here, we present an overview of the complex issues from
a healthcare delivery perspective.
Introduction
Chronic heart failure is getting more complex, with
patients becoming older and accumulating more comorbid-
ities.1–3 In addition, guideline-directed therapies improve
cardiac outcomes4–6 with the effect that the longevity of
heart failure patients increases and the burden of
age-related non-cardiac diseases rises in parallel to the
duration of the syndrome.7,8 Non-cardiac diseases have
an adverse effect on outcomes and, in particular, on hospi-
talization rates, with the number of non-cardiac comorbid-
ities having an additive effect of the complication
rates.9,10 Taking into account these issues, a multidiscipli-
nary panel of leading international experts has been orga-
nized by the Heart Failure Association of European Society
of Cardiology (ESC) to discuss the latest evidence, ongoing
research, and controversial issues regarding physiological
monitoring in the complex multimorbid heart failure
patient. The papers in this supplement reflect the key
points raised during these meetings.
General considerations
Drugs used to treat comorbidities can have a negative im-
pact on heart failure outcomes and, in particular, might af-
fect renal outcomes (like non-steroidal antagonists), which
in turn affect morbidity and mortality in chronic heart fail-
ure.11 Impaired renal function interferes with guideline-
directed medical therapies, which are often dependent on
renal function (renin–angiotensin–aldosterone inhibitors).4
Cognitive dysfunction and depression affect the adherence
to guideline-directed therapies and impair healthcare
literacy, with detrimental impact on adherence to heart
failure therapies.12–14
Therefore, the monitoring of the complex multimorbid
patient is multidisciplinary. As such, it needs to be per-
formed by heart failure specialists and specialists in
other fields using a mutual approach. In particular, this
approach needs to be organized in specialized pro-
grammes, because these patients have a high rate of
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hospitalizations.15 Beyond this, self-care skills need to
be fostered, including patient education and incorporat-
ing shared decision-making into the concept of the com-
plex patient care.
Medical adherence
Medical adherence is one of the major precipitating causes
of acute heart failure.16,17 Medical adherence is related to
a poor degree of health literacy, cognitive dysfunction, and
depression18 and is inversely related to the number of con-
text to health care providers.19 Monitoring of drug thera-
pies is usually performed by direct contact of the patients
with physicians or healthcare nurses.20,21 However, tele-
monitoring approaches have been tested, although most
experiences are present in hypertension.22 Due to the high
prevalence of comorbidities, it became clear that the com-
prehensive heart failure care must involve a multidiscipli-
nary approach (Figure 1).
Management of comorbidities
According to the majority of disease management pro-
grammes, a regular patient contact is necessary to obtain
signs, symptoms and potentially laboratory tests for the
major comorbidities. These include renal dysfunction,
hyperkalaemia, anaemia, iron deficiency, thyroid disease,
and electrolyte disturbances.23–26 Even subtle symptoms
should be considered and regular physician-patient con-
tacts or heart failure nurse–patient contacts shall be main-
tained, as recommended in major disease management
programmes and heart failure network programmes.27
In particular, new introduction of drugs such as mineralo-
corticoid antagonists, in particular in combination with
angiotensin-converting enzyme-inhibitors or angiotensin-
receptor blockers, should lead to a regular monitoring of
electrolytes, which has been insufficiently performed in
real-world studies.4,28
Education of healthcare providers
Psychological aspects affect healthcare behaviour and
medical adherence. Therefore, monitoring should be made
by specialists in depressive symptoms and cognitive dys-
function, as both are frequently found in patients with
heart failure and in the elderly population. Furthermore,
medical devices like implantable cardioverter-defibrilla-
tors (assist devices) and concomitant diseases and
complications might induce a loss of trust in medical inter-
ventions by heart failure patients. Therefore, regular com-
munication including psychological counselling involving
families and other care providers is of particular impor-
tance. The threshold to contact a specialist for psychologi-
cal dysfunction should be low (i.e. also in presence of mild
symptoms).
Monitoring after discharge
Discharge planning is one of the most important factors to
maintain medical care, which has been initiated during an
in-hospital stay. Discharge planning should allow patients
to see physicians or heart failure nurses within a short pe-
riod of time to allow them to respond to any changes in
signs and symptoms.27 The change from the in-hospital sit-
uation to the out-hospital setting requires close counselling
for lifestyle advice in the changing environment.27
Counselling is not only important shortly after discharge to
address the so-called ‘vulnerable phase’. Also long-term
follow-up and regular consultation to advise for lifestyle,
exercise, medical treatments and to increase patient’s
Figure 1 Multidisciplinary care of heart failure patients involving many disciplines to account for multimorbidity and psychosocial demands.
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awareness on signs and symptoms of the disease is of cru-
cial importance. The regular consultation should be accom-
panied by monitoring of laboratory values for renal
function, iron deficiency, anaemia, and potentially natri-
uretic peptide as well as a rigorous physical examination.4
Patients eligible for telemonitoring or implantable moni-
toring devices should be carefully evaluated by an expert
physician to improve hemodynamic monitoring. Selected
patients should be carefully evaluated for these innovative
possibilities.
Conclusions
Chronic heart failure patients are commonly burdened by
multiple comorbidities, which require a systematic moni-
toring over time. Key factors to be monitored are lung con-
gestion or total body water monitoring, renal impairment,
haemoglobin and serum iron, transferrin and transferrin
saturation, sodium, potassium, sleep-disordered breath-
ing, and of coursemonitoring diabetic control.29
Also, there is a growing incidence of non-cardiac comor-
bidities. Often heart failure patients are burdened by co-
existing cancer, with the need to develop evidence-based
strategies for monitoring and protecting cardiac function
during anti-cancer regimes.29
Finally, psychological and cognitive aspects must be
carefully monitored over time due to their link with poor
adherence and prognosis.
For all these reasons, physiological monitoring in the
multimorbid heart failure patient is particularly challeng-
ing and upcoming research with clinical trials specifically
including old and multimorbid patients are strongly
needed.
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